Krystal Biotech, Inc.
KRYS
$168.57
$3.872.35%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 8.70% | 19.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.70% | 19.29% | |||
| Cost of Revenue | -25.96% | 11.23% | |||
| Gross Profit | 11.71% | 20.04% | |||
| SG&A Expenses | 8.97% | 3.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.74% | -0.63% | |||
| Operating Income | 18.45% | 65.83% | |||
| Income Before Tax | 63.29% | 85.53% | |||
| Income Tax Expenses | 20.93% | 442.77% | |||
| Earnings from Continuing Operations | 67.33% | 74.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 67.33% | 74.59% | |||
| EBIT | 18.45% | 65.83% | |||
| EBITDA | 18.06% | 57.70% | |||
| EPS Basic | 67.10% | 73.86% | |||
| Normalized Basic EPS | 14.85% | 47.48% | |||
| EPS Diluted | 67.71% | 71.70% | |||
| Normalized Diluted EPS | 15.08% | 46.76% | |||
| Average Basic Shares Outstanding | 0.14% | 0.41% | |||
| Average Diluted Shares Outstanding | -0.06% | 0.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||